NEW DELHI: Traditional medicine is slowly getting the recognition it hadn’t received at the national forums in the past. Blame it on the negative perceptions or stereotyping that despite its enormous potential, Ayurveda was not being taken seriously.
In one of the examples of changing scenario, the agreement for commercialization of two Ayurvedic formulations for treatment of Malaria and Diabetes respectively was signed between the National Research Development Corporation (NRDC), an Enterprise of the Department of Scientific & Industrial Research and Dabur India.
Both Ayush-64, an Ayurvedic formulation for treatment of Malaria and Ayush-82, an ayurvedic formulation for management of Diabetes have been developed by Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, an Autonomous body of the Ministry of AYUSH (Ayurveda, Yoga and naturopathy, Unani, Siddha and Homeopathy).
While Ayush-64 is a poly-herbal non-toxic drug has been developed by CCRAS after carrying out extensive pharmacological, toxicological and clinical studies, Ayush-82; an anti diabetic drug also developed by CCRAS is a combination of known and tested hypoglycemic drugs. The use of these two drugs is expected to help millions of people suffering from Malaria and Diabetes.
The licence agreements were signed by Dr H Purushotham on behalf of National Research Development Corporation, New Delhi and Dr J L N Sastry, Head Healthcare Research, on behalf of Dabur India, New Delhi at NRDC Office in the presence of Mr B N Sarkar, Scientist (F), Department of Scientific and Industrial Research, New Delhi and Director, NRDC Board and other Senior executives of NRDC and Dabur.
Present on the occasion was the Minister of State, Ministry of AYUSH, Mr Shripad Yesso Naik and Secretary AYUSH, Mr Ajit M Sharan, NRDC a government technology licensing agency has so far licensed about 10 technologies developed by CCRAS to more than 30 companies in India.
